1. Home
  2. BCDA vs JVA Comparison

BCDA vs JVA Comparison

Compare BCDA & JVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCDA
  • JVA
  • Stock Information
  • Founded
  • BCDA N/A
  • JVA 1971
  • Country
  • BCDA United States
  • JVA United States
  • Employees
  • BCDA N/A
  • JVA N/A
  • Industry
  • BCDA Biotechnology: Pharmaceutical Preparations
  • JVA Packaged Foods
  • Sector
  • BCDA Health Care
  • JVA Consumer Staples
  • Exchange
  • BCDA Nasdaq
  • JVA Nasdaq
  • Market Cap
  • BCDA 9.4M
  • JVA 7.8M
  • IPO Year
  • BCDA N/A
  • JVA 2005
  • Fundamental
  • Price
  • BCDA $2.83
  • JVA $2.43
  • Analyst Decision
  • BCDA Strong Buy
  • JVA
  • Analyst Count
  • BCDA 1
  • JVA 0
  • Target Price
  • BCDA $60.00
  • JVA N/A
  • AVG Volume (30 Days)
  • BCDA 80.6K
  • JVA 105.1K
  • Earning Date
  • BCDA 08-07-2024
  • JVA 09-12-2024
  • Dividend Yield
  • BCDA N/A
  • JVA N/A
  • EPS Growth
  • BCDA N/A
  • JVA N/A
  • EPS
  • BCDA N/A
  • JVA 0.07
  • Revenue
  • BCDA $468,000.00
  • JVA $73,062,901.00
  • Revenue This Year
  • BCDA N/A
  • JVA N/A
  • Revenue Next Year
  • BCDA $436.41
  • JVA N/A
  • P/E Ratio
  • BCDA N/A
  • JVA $37.57
  • Revenue Growth
  • BCDA N/A
  • JVA 10.45
  • 52 Week Low
  • BCDA $2.62
  • JVA $0.67
  • 52 Week High
  • BCDA $23.25
  • JVA $3.25
  • Technical
  • Relative Strength Index (RSI)
  • BCDA 36.56
  • JVA 57.69
  • Support Level
  • BCDA $2.85
  • JVA $2.00
  • Resistance Level
  • BCDA $3.66
  • JVA $3.25
  • Average True Range (ATR)
  • BCDA 0.29
  • JVA 0.29
  • MACD
  • BCDA 0.04
  • JVA 0.03
  • Stochastic Oscillator
  • BCDA 13.54
  • JVA 42.25

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

About JVA Coffee Holding Co. Inc.

Coffee Holding Co Inc is engaged in the business of wholesale coffee operations, including manufacturing, roasting, packaging, marketing and distributing roasted and blended coffees for private labeled accounts and its own brands, and it sells green coffee. Its products include wholesale green coffee, private-label coffee, and branded coffee. The company sells its coffee products throughout the United States, Canada and certain countries in Asia.

Share on Social Networks: